(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vacation destinations in America - 2Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- 3Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- 4Meet the Stars of the Feline World: Well known Pet Feline Varieties
- 5Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- Deadly Switzerland ski resort fire was likely started by sparklers attached to champagne bottles, officials say
- Partner of crime boss Steven Lyons arrested in Dubai
- Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- Drenched in Pixels: A Survey of \Vivid Interactivity Experience\ Game
- December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- Experience Is standing by: History's Most noteworthy Travelers
- Drones haven't won the fight in Ukraine. That matters as the West learns new ways of war.
- Iran's stolen futures: The arrested Iranians at risk of execution by the regime
